Physician profile
Matthew Zipoli
NPI 1093784159
$745.73
in general payments reported to CMS, 2019-2025
15 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.39 · 2022: $106 · 2024: $27.51 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $543 · Education: $47.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.45 |
| Education | $47.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $196.68 | 2022-2025 | |
| Lilly USA, LLC | $94.73 | 2021-2025 | Ebglyss, Taltz |
| Janssen Biotech, INC. | $92.50 | 2021-2025 | Tremfya |
| Incyte Corporation | $57.13 | 2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $46.38 | 2025 | |
| Ucb, INC. | $44.40 | 2025 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $38.38 | 2025 | Valchlor |
| Amgen INC. | $27.51 | 2024 | Otezla |
| Leo Pharma INC. | $27.28 | 2025 | Anzupgo |
| Pfizer INC. | $23.97 | 2025 | |
| Lnhc, INC | $23.94 | 2025 | Zelsuvmi |
| Galderma Laboratories, L.P. | $19.67 | 2025 | Nemluvio |
| Mimedx Group, INC. | $19.48 | 2025 | |
| Strata Skin Sciences, INC. | $16.88 | 2025 | Xtrac |
| Biofrontera INC. | $16.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Zipoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.